Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleSystematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis

Ana-Maria Orbai, Joshua Weitz, Evan L. Siegel, Stefan Siebert, Laura J. Savage, Sibel Z. Aydin, Jolanda J. Luime, Ori Elkayam, Barbara Neerinckx, Slavo Urbancek, Kurt de Vlam, Christopher T. Ritchlin and the GRAPPA Enthesitis Working Group
The Journal of Rheumatology November 2014, 41 (11) 2290-2294; DOI: https://doi.org/10.3899/jrheum.140878
Ana-Maria Orbai
From Johns Hopkins Arthritis Center, Baltimore, Maryland; Dermatology Associates of Rochester, Rochester, New York; Arthritis and Rheumatism Associates, Rockville, Maryland, USA; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, Koc University, Faculty of Medicine, Istanbul, Turkey; Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Rheumatology, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; University Hospital Leuven, Leuven, Belgium; Department of Dermatology, F.D. Roosevelt Hospital, Banska Bystrica, Slovakia; and Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: aorbai1@jhmi.edu
Joshua Weitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan L. Siegel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Siebert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura J. Savage
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sibel Z. Aydin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jolanda J. Luime
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ori Elkayam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Neerinckx
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Slavo Urbancek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kurt de Vlam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher T. Ritchlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Enthesitis is a characteristic feature of psoriatic arthritis (PsA) and is important in disease pathogenesis and classification. Use of clinical outcome measures for enthesitis is heterogeneous, and only 1 measure has been specifically developed and validated in PsA. Ultrasound and magnetic resonance imaging assessments of enthesitis may have advantages over clinical examination but are insufficiently studied. As part of an update of treatment recommendations by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), we performed a systematic literature review and identified randomized controlled trials with enthesitis outcomes in PsA. For each treatment agent we calculated treatment effect sizes (where applicable) and graded the level of evidence.

Key Indexing Terms:
  • ENTHESITIS
  • ENTHESOPATHY
  • PSORIATIC ARTHRITIS
  • OUTCOME MEASURES
  • TREATMENT

Enthesitis or inflammation at sites where ligaments, tendons, and joint capsules attach to bone (1) is prevalent (25%–78%) in psoriatic arthritis (PsA); (2) may be the initial inflammatory manifestation1; and (3) may be centrally involved in disease pathogenesis in PsA2,3. While the entheses have become a key outcome in clinical trials4, a number of enthesitis instruments are available, and 5 different enthesitis outcome measures were used across 12 clinical trials (Table 1). The Leeds Enthesitis Index (LEI)5 is the only enthesitis measure developed and validated for PsA.

View this table:
  • View inline
  • View popup
Table 1.

Enthesitis measures used in randomized controlled trials in psoriatic arthritis.

Both power Doppler ultrasound (PDUS) and magnetic resonance imaging (MRI) can identify both inflammatory and chronic changes, with PDUS providing additional information on vascularity, and MRI on osteitis; thus enthesitis can be detected at earlier stages and with greater sensitivity. Sensitivity to change of both imaging modalities for enthesitis has been shown in various studies, supporting their use in clinical trials.

MATERIALS AND METHODS

In a centralized systematic literature search performed by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) to support evidence-based updated treatment recommendations for PsA manifestations6, 32 full-text articles were identified for enthesitis in PsA. Eligibility for inclusion in the enthesitis review was defined as interventional randomized controlled trials (RCT) with enthesitis outcomes performed in PsA. Of these 32 full-text articles, 15 did not correspond regarding study design (open-label, case-control, case report, comment, review); 1 study reported additional results of a trial already included7; 7 did not report on PsA; and 2 did not report enthesitis outcomes; therefore, 7 of those initially identified full-text articles remained and are included here8,9,10,11,12,13,14.

The GRAPPA Enthesitis Working Group also included the first double-blind RCT in PsA with enthesitis outcomes15, and several additional RCT that were searched by hand after consulting experts in the field. Thus, 5 articles, representing the initial sulfasalazine trial in PsA15 and trials completed after the date of the initial literature search16,17,18,19, were added to the initial 7 articles8,9,10,11,12,13,14, for a total of 12 articles included in this review.

A standardized data collection form was used to extract study information (year, author, journal); study type; participant diagnosis; treatment and comparator drug; dose; number of participants; enthesitis measure(s) and assessment technique; mean (SD) scores at baseline and followup; mean (SD) change scores; and percentage with enthesitis at baseline and followup. Two independent reviewers extracted data (AO, JW). Where applicable, effect size calculations were based on mean score change and baseline standard deviation in the treatment and placebo groups, respectively. We used Stata statistical software (Stata 13, StataCorp LP) for Cohen’s d effect size calculations20.

RESULTS

Enthesitis measures used across PsA RCT are summarized in Table 1. Effects of various agents on enthesitis in PsA RCT are summarized in Table 2.

View this table:
  • View inline
  • View popup
Table 2.

Treatment effectiveness for enthesitis outcomes in randomized controlled trials in psoriatic arthritis.

Sulfasalazine

In this study, which used the most complex enthesitis index, the modified Mander Enthesitis Index, the change in score was not statistically significant between treatment and placebo15.

Infliximab

In 2 infliximab trials (IMPACT 1 and 2), the IMPACT Index was used to assess enthesitis. Post-treatment percentages of patients with enthesopathy were statistically significantly smaller for infliximab versus placebo (14% vs 31%, p = 0.021; and 20% vs 37%, p = 0.002, respectively)8,9. Mean change scores, required for effect size calculation, were not reported.

Adalimumab

The adalimumab trials assessed the IMPACT Index. Mean scores were not reported in the ADEPT trial (exploratory endpoint)10, and in the second trial, mean change scores were not statistically different between adalimumab and placebo at 16 weeks (–0.5 vs –0.2, p > 0.05)11.

Golimumab

The PsA modified Maastricht Ankylosing Spondylitis Enthesitis Score (PsA-modified MASES) was used in the GO-REVEAL trial7,12. Differences in mean percentage change scores at 24 weeks were significant between each golimumab group (50 mg, 100 mg, and overall) and placebo (not tested between the active arms). Effect sizes were −0.49 (95% CI −0.7, −0.2) for golimumab 50 mg and −0.62 (95% CI −0.9, −0.4) for golimumab 100 mg. Posthoc analysis of MASES change scores similarly favored golimumab (no baseline MASES scores were given to allow effect size calculations)7.

Etanercept

Enthesitis was not an outcome in the initial etanercept trial in PsA21. In the observational PRESTA trial14, where 2 active arms of etanercept were compared, no differences were observed between the groups in percentages with enthesitis (IMPACT Index); 70% and 80% of patients had improved IMPACT enthesitis scores at 12 and 24 weeks, respectively (no placebo comparison arm).

Certolizumab

In the RAPID-PsA trial17, differences in the LEI at 24 weeks were statistically significant in favor of certolizumab versus placebo. Participants in this trial included patients previously treated with an anti-tumor necrosis factor (TNF) agent (20%). Effect sizes were −0.4 (95% CI −0.7, −0.2) for certolizumab 400 mg monthly and −0.6 (95% CI −0.8, −0.3) for certolizumab 200 mg every 2 weeks.

Ustekinumab

In the initial ustekinumab trial13, percentages of patients with enthesitis (IMPACT Index) at 12 weeks were statistically significantly smaller for ustekinumab versus placebo (23% vs 42%, p = 0.016). In the P-SUMMIT 1 and 2 trials 16,19, using the PsA-modified MASES score, differences between mean enthesitis scores at 24 weeks were statistically significant only in the P-SUMMIT 1 trial for the ustekinumab 90-mg group and for the combined ustekinumab group versus placebo, respectively. In the P-SUMMIT 1 trial, effect size was −0.3 (95% CI −0.5, −0.1) for ustekinumab 90 mg, not significant for 45 mg [–0.19 (95% CI −0.4, 0)], and −0.25 (95% CI −0.4, −0.1) for the ustekinumab arms combined. In the P-SUMMIT 2 trial, which mainly included participants previously treated with anti-TNF agents (> 60%), effect size was not different than 0 [–0.24 (95% CI −0.5, 0.3) for ustekinumab 90 mg; −0.19 (95% CI −0.5, 0.1) for ustekinumab 45 mg; and −0.22 (95% CI −0.5, 0.1) for the ustekinumab arms combined].

At 24 weeks, percentages of patients with enthesitis as determined by PsA-modified MASES were statistically significantly smaller for ustekinumab versus placebo in both P-SUMMIT trials (percentage of patients with enthesitis in P-SUMMIT1: ustekinumab 90 mg: 61%; ustekinumab 45 mg: 69%; placebo: 81%, p values: ustekinumab vs placebo 0.0002 and 0.0179, respectively; in P-SUMMIT2: ustekinumab 90 mg: 70%; ustekinumab 45 mg: 76%; placebo: 88%, p values ustekinumab vs placebo < 0.01 and < 0.05, respectively).

Apremilast

In the apremilast trial18, mean enthesitis change score on the MASES index at 24 weeks was statistically significantly in favor of apremilast 30 mg (twice daily) versus placebo [effect size −0.3 (95% CI −0.5, −0.1)]. Mean change score was not significant versus placebo in the apremilast 20 mg arm.

Glucocorticoid injections

A recent systematic review and metaanalysis of controlled studies of local glucocorticoid injections in tendinopathy (not limited to enthesitis) found impaired tendon healing (necrosis, collagen fiber disorganization) and decreased mechanical properties22. Limitations of the metaanalysis included heterogeneity of glucocorticoid substances used across studies (dexamethasone, triamcinolone, methylprednisolone, hydrocortisone, and various combinations of these); heterogeneity in sites injected across studies (Achilles/shoulder/forearm/peroneal/patellar tendons); and no information was collected on the exact injection techniques.

Effectiveness of Various Agents for Enthesitis in PsA (level of evidence)

  • Effective (1b): Infliximab; golimumab; certolizumab; ustekinumab; apremilast (30 mg twice daily).

  • Not effective (1b): Sulfasalazine (2 g daily).

  • Not adequately studied: Adalimumab; other disease-modifying antirheumatic drugs (including methotrexate); nonsteroidal antiinflammatory drugs; physiotherapy.

  • Not studied in PsA enthesitis: Local glucocorticoid injections.

  • Associated with worse outcomes: Glucocorticoid injections in tendinopathy (2a).

DISCUSSION

Although the LEI, the PsA-modified MASES, and the MASES showed responsiveness to change in clinical trials, establishing a minimal clinically important difference and selecting a single enthesitis instrument are the next critical steps required to consistently measure enthesitis outcomes. Additionally, understanding efficacy of various agents is challenging in the absence of head-to-head randomized clinical trials.

Individual anti-TNF agents have shown effectiveness for enthesitis, with moderate treatment effect size for golimumab and certolizumab23 and significant percentage improvement for infliximab; the exceptions are etanercept and adalimumab, for which evidence is inconclusive due to limitations of study design: no placebo arm and inadequate sample size (exploratory endpoint), respectively; and severe limitations of the scoring measure used (poor responsiveness and inter-rater reliability of the IMPACT Index)5,24. We can conclude based on high quality clinical trial data available for infliximab, golimumab, and certolizumab that anti-TNF agents are effective for enthesitis as a class, which is expected based on the pathophysiology of enthesial inflammation where TNF plays a central role2.

In addition to anti-TNF agents, ustekinumab and apremilast are also effective for enthesitis in PsA, based on limited high quality clinical trial data. These findings underscore a potential role for interleukin 12 (IL-12), IL-23, and IL-17, as well as for other upstream key molecules such as anti-phosphodiesterase 4, suggesting these pathways may be involved in the pathogenesis of enthesitis.

In conclusion, high quality data from clinical trials are now available to support efficacy of anti-TNF agents, ustekinumab, and apremilast for enthesitis in PsA.

Acknowledgment

We thank Janssen Pharmaceuticals for making data available for effect size calculations for ustekinumab and apremilast. We thank Linda Melvin, BA, for editorial assistance.

REFERENCES

  1. 1.↵
    1. Sakkas LI,
    2. Alexiou I,
    3. Simopoulou T,
    4. Vlychou M
    . Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 2013;43:325–34.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Ritchlin CT
    . Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005;17:406–12.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Aydin SZ,
    2. Ash ZR,
    3. Tinazzi I,
    4. Castillo-Gallego C,
    5. Kwok C,
    6. Wilson C,
    7. et al.
    The link between enthesitis and arthritis in psoriatic arthritis: A switch to a vascular phenotype at insertions may play a role in arthritis development. Ann Rheum Dis 2013;72:992–5.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Smolen JS,
    2. Braun J,
    3. Dougados M,
    4. Emery P,
    5. Fitzgerald O,
    6. Helliwell P,
    7. et al.
    Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: Recommendations of an international task force. Ann Rheum Dis 2014;73:6–16.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Healy PJ,
    2. Helliwell PS
    . Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686–91.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Coates LC,
    2. Ritchlin CT,
    3. Kavanaugh AF
    . GRAPPA treatment recommendations: An update from the GRAPPA 2013 Annual Meeting. J Rheumatol 2014;41:1237–9.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Kavanaugh A,
    2. Mease P
    . Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). J Rheumatol Suppl 2012;89:90–3.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Antoni CE,
    2. Kavanaugh A,
    3. Kirkham B,
    4. Tutuncu Z,
    5. Burmester GR,
    6. Schneider U,
    7. et al.
    Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227–36.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Antoni C,
    2. Krueger GG,
    3. de Vlam K,
    4. Birbara C,
    5. Beutler A,
    6. Guzzo C,
    7. et al.
    Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150–7.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Mease PJ,
    2. Gladman DD,
    3. Ritchlin CT,
    4. Ruderman EM,
    5. Steinfeld SD,
    6. Choy EH,
    7. et al.
    Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279–89.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Genovese MC,
    2. Mease PJ,
    3. Thomson GT,
    4. Kivitz AJ,
    5. Perdok RJ,
    6. Weinberg MA,
    7. et al.
    Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040–50.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Kavanaugh A,
    2. McInnes I,
    3. Mease P,
    4. Krueger GG,
    5. Gladman D,
    6. Gomez-Reino J,
    7. et al.
    Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976–86.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Gottlieb A,
    2. Menter A,
    3. Mendelsohn A,
    4. Shen YK,
    5. Li S,
    6. Guzzo C,
    7. et al.
    Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633–40.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Sterry W,
    2. Ortonne JP,
    3. Kirkham B,
    4. Brocq O,
    5. Robertson D,
    6. Pedersen RD,
    7. et al.
    Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Clegg DO,
    2. Reda DJ,
    3. Mejias E,
    4. Cannon GW,
    5. Weisman MH,
    6. Taylor T,
    7. et al.
    Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013–20.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. McInnes IB,
    2. Kavanaugh A,
    3. Gottlieb AB,
    4. Puig L,
    5. Rahman P,
    6. Ritchlin C,
    7. et al.
    Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780–9.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Mease PJ,
    2. Fleischmann R,
    3. Deodhar AA,
    4. Wollenhaupt J,
    5. Khraishi M,
    6. Kielar D,
    7. et al.
    Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48–55.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Kavanaugh A,
    2. Mease PJ,
    3. Gomez-Reino JJ,
    4. Adebajo AO,
    5. Wollenhaupt J,
    6. Gladman DD,
    7. et al.
    Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020–6.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Ritchlin C,
    2. Rahman P,
    3. Kavanaugh A,
    4. McInnes IB,
    5. Puig L,
    6. Li S,
    7. et al.
    Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990–9.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Cohen J
    . Statistical power analysis for the behavioral sciences. 2nd ed.Hillsdale, NJ: Erlbaum; 1988.
  21. 21.↵
    1. Mease PJ,
    2. Goffe BS,
    3. Metz J,
    4. VanderStoep A,
    5. Finck B,
    6. Burge DJ
    . Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000;356:385–90.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Dean BJ,
    2. Lostis E,
    3. Oakley T,
    4. Rombach I,
    5. Morrey ME,
    6. Carr AJ
    . The risks and benefits of glucocorticoid treatment for tendinopathy: A systematic review of the effects of local glucocorticoid on tendon. Semin Arthritis Rheum 2014;43:570–6.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Cohen J
    . A power primer. Psychol Bull 1992;112:155–9.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Gladman DD,
    2. Inman RD,
    3. Cook RJ,
    4. Maksymowych WP,
    5. Braun J,
    6. Davis JC,
    7. et al.
    International spondyloarthritis interobserver reliability exercise—the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007;34:1740–5.
    OpenUrlAbstract/FREE Full Text
  25. 25.
    1. Clegg DO,
    2. Reda DJ,
    3. Weisman MH,
    4. Blackburn WD,
    5. Cush JJ,
    6. Cannon GW,
    7. et al.
    Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004–12.
    OpenUrlCrossRefPubMed
  26. 25a.
    1. Mander M,
    2. Simpson JM,
    3. McLellan A,
    4. Walker D,
    5. Goodacre JA,
    6. Dick WC
    . Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197–202.
    OpenUrlAbstract/FREE Full Text
  27. 26.
    1. Heuft-Dorenbosch L,
    2. Spoorenberg A,
    3. van Tubergen A,
    4. Landewe R,
    5. van ver Tempel H,
    6. Mielants H,
    7. et al.
    Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127–32.
    OpenUrlAbstract/FREE Full Text
  28. 27.
    1. Ibrahim G,
    2. Groves C,
    3. Chandramohan M,
    4. Beltran A,
    5. Valle R,
    6. Reyes B,
    7. et al.
    Clinical and ultrasound examination of the Leeds Enthesitis Index in psoriatic arthritis and rheumatoid arthritis. ISRN Rheumatol 2011:731917.
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 11
1 Nov 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis
Ana-Maria Orbai, Joshua Weitz, Evan L. Siegel, Stefan Siebert, Laura J. Savage, Sibel Z. Aydin, Jolanda J. Luime, Ori Elkayam, Barbara Neerinckx, Slavo Urbancek, Kurt de Vlam, Christopher T. Ritchlin, the GRAPPA Enthesitis Working Group
The Journal of Rheumatology Nov 2014, 41 (11) 2290-2294; DOI: 10.3899/jrheum.140878

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis
Ana-Maria Orbai, Joshua Weitz, Evan L. Siegel, Stefan Siebert, Laura J. Savage, Sibel Z. Aydin, Jolanda J. Luime, Ori Elkayam, Barbara Neerinckx, Slavo Urbancek, Kurt de Vlam, Christopher T. Ritchlin, the GRAPPA Enthesitis Working Group
The Journal of Rheumatology Nov 2014, 41 (11) 2290-2294; DOI: 10.3899/jrheum.140878
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • Effectiveness of Various Agents for Enthesitis in PsA (level of evidence)
    • DISCUSSION
    • Acknowledgment
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

ENTHESITIS
ENTHESOPATHY
PSORIATIC ARTHRITIS
OUTCOME MEASURES
TREATMENT

Related Articles

Cited By...

More in this TOC Section

  • Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review
  • Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the GRAPPA
Show more Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Similar Articles

Keywords

  • ENTHESITIS
  • ENTHESOPATHY
  • psoriatic arthritis
  • outcome measures
  • treatment

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire